Feb. 17, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Retia Medical's Argos Infinity, the company's cardiovascular intelligence software platform designed for high-risk surgical and critical care environments across health systems.

Feb. 13, 2026 — Conavi Medical Corp. recently highlighted the publication of new peer-reviewed research titled “Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head-to-head comparison against histology,” published in Cardiovascular Research by the European Society of Cardiology.

Dec. 10, 2025 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to HeartBeam, Inc. for its 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior Not Substantially Equivalent (NSE) determination.

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their institutions and research projects, as recipient of the 2026 ARRS Resident/Fellow in Radiology Awards:

cardiac MRI, biomarkers, Cardiovascular disease, cardiomyopathy,

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect that heart and vessels such as coronary artery disease, stroke, hypertension and peripheral artery disease. Another class of cardiovascular diseases that have received a lot of attention in the last decade are rare CVDs (RCD) that affect few people and include conditions such as Fabry disease (FD), cardiac amyloidosis (CA) and hypertrophic cardiomyopathy (HCM).

Feb. 12, 2026 — ACIST Medical Systems, Inc., a Bracco Group company, has announced the launch in selected markets in Europe of the ACIST Pro Diagnostic System, a next-generation variable-rate contrast management solution designed to advance precision, safety and efficiency in image-guided cardiovascular procedures.

Feb. 12, 2026 – CellProthera has acquired the transendocardial catheter originally developed by Celyad Oncology. This acquisition is a critical step for CellProthera as it prepares to enter the pivotal Phase 3 clinical trial.  The transendocardial catheter is a key enabling technology of its therapeutic approach, delivering targeted application of proprietary processed CD34 + stem cells directly into damaged cardiac tissue.

Feb. 11, 2026 – Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a national leader in strategic program development for cardiovascular services, have partnered to deliver unique accreditation services for open-heart surgery programs nationwide.

Feb. 11, 2026 — The Northwestern Medicine Bluhm Cardiovascular Institute (BCVI) in Chicago has received a $50 million from philanthropist Neil G. Bluhm and the Bluhm Family Foundation. The gift builds on two decades of generosity from Bluhm, bringing his total gifts to BCVI to $135 million.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now